Targeted Industries Position QI Path as a risk intelligence solution for high-stakes sectors such as healthcare, biopharma, and government. Emphasize the platform’s ability to proactively identify and mitigate vulnerabilities in clinical trials, drug manufacturing, and operational readiness to open conversations with investors, CROs, pharma manufacturers, hospitals, and government contractors.

Proactive Risk Focus Highlight the AI-powered ARIS Adaptive Risk Intelligence System that automates risk detection and proactive planning. Use this to pitch value in reducing waste, rework, and uncertainty, especially for mission-critical initiatives in regulated environments where compliance and safety are paramount.

Structured Collaboration Promote the QIP System as a cloud-based platform that guides cross-functional teams. Sell enhancements around cross-department risk visibility, faster decision cycles, and structured problem-solving to CIOs, CISO offices, and program leadership seeking improved execution.

Growth Pathways Leverage the company’s mid-market footprint (11-50 employees) to target mid-sized healthcare providers, biotech firms, and government programs undergoing modernization. Offer scalable pilots and phased deployments to demonstrate ROI before broader adoption.

Funding Signals With revenue in the low single to mid single digits and a focus on high-compliance sectors, approach potential partners and customers that are budgeting for risk management, quality assurance, and operational resilience initiatives. Use case studies from healthcare and biopharma to illustrate tangible financial and time-to-value benefits.